Pluri (NASDAQ:PLUR) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.32) by 25 percent. This is a 29.41 percent increase over losses of $(0.34) per share from the same period last year.
Castle Biosciences Announces Preliminary Q4 And FY23 Results; Expects To Deliver More Than $210M For FY23 Total Revenue Vs $203.95M Est.; Year-End 2023 Cash, Cash Equivalents And Marketable Investment Securities Expected To Be ~$243M
Expect to deliver 2023 total revenue of more than $210 million, at least 53% growth over 2022Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022Year-end 2023 cash, cash equivalents and
